EUVIMEDEUVIMED entdecken
Crossref

Evaluation of treatment response to generic imatinib in newly diagnosed low-risk Ph+ CML patients

Dr. Muhammad Fahad Akbar, Dr Muhammad Tahir, Dr. Rizwan Munir

Anaesthesia, Pain & Intensive Care · 04.10.2026 · 30 (7)

DOI: 10.35975/apic.v30i7.3305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anaesthesia, Pain & Intensive Care, online erschienen am 04.10.2026. Verfasst von Dr. Muhammad Fahad Akbar und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic myeloid leukemia (CML) is a myeloproliferative disorder driven by the BCR-ABL fusion gene. Imatinib, a first-generation tyrosine kinase inhibitor, remains the standard first-line therapy.

Objective

To evaluate the treatment response to generic imatinib in newly diagnosed low-risk Philadelphia chromosome-positive CML patients. Methodology: This quasi-experimental study was conducted at the Department of Oncology, Allied Hospital Faisalabad, from February 2025 to March 2026. A total of 174 patients were enrolled using non-probability consecutive sampling. Eligible patients were newly diagnosed, untreated low-risk Ph+ CML cases aged 18–60 years. All patients received generic imatinib at a dose of 300 mg twice daily. Baseline and three-month assessments included complete blood counts and quantitative BCR-ABL PCR.

Results

The mean age of patients was 38.6 ± 10.2 years, with 58.0% males. CHR was achieved in 85.6% of patients. Complete cytogenetic response was observed in 69.5%, while 29.9% achieved MMR at three months. There was a significant reduction in mean BCR-ABL levels from 78.4 ± 12.6% at baseline to 6.2 ± 3.8% at three months (p < 0.001). Significant associations with CHR were observed for age (p=0.041), gender (p=0.032), splenomegaly (p=0.018), and treatment compliance (p < 0.001). Most patients experienced no or mild adverse effects.

Conclusion

Generic imatinib is an effective, safe, and well-tolerated treatment option in newly diagnosed low-risk Ph+ CML patients, demonstrating high early response rates and significant molecular reduction, with treatment adherence playing a critical role in achieving optimal outcomes. Keywords: Chronic myeloid leukemia, Imatinib, Generic drugs, BCR-ABL, Hematologic response, Molecular response Citation: Akbar MF, Tahir M, Munir R. Evaluation of Treatment Response to Generic Imatinib in Newly DiagnosedLow-Risk Ph+ CML Patients. Anaesth. pain intensive care 2026;30(7). DOI: 10.35975/apic.v30i7.3305 Received: March 31, 2026 ; Revised: xxxxxxxx; Accepted: May 04, 2026

Zitieren

APA

Akbar, D. M. F., Tahir, D. M., & Munir, D. R. (2026). Evaluation of treatment response to generic imatinib in newly diagnosed low-risk Ph+ CML patients. Anaesthesia, Pain & Intensive Care, 30(7). https://doi.org/10.35975/apic.v30i7.3305

Vancouver

Akbar DMF, Tahir DM, Munir DR. Evaluation of treatment response to generic imatinib in newly diagnosed low-risk Ph+ CML patients. Anaesthesia, Pain & Intensive Care. 2026;30(7). doi:10.35975/apic.v30i7.3305

BibTeX
@article{Akbar2026,
  author = {Akbar, Dr. Muhammad Fahad and Tahir, Dr Muhammad and Munir, Dr. Rizwan},
  title = {Evaluation of treatment response to generic imatinib in newly diagnosed low-risk Ph+ CML patients},
  journal = {Anaesthesia, Pain & Intensive Care},
  year = {2026},
  volume = {30},
  number = {7},
  doi = {10.35975/apic.v30i7.3305}
}
Kostenlos starten →